patientholders

175 results found.

Top Stocks matching your search for "patient holders"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
HKD

AMTD Digital Inc - ADR

-24.37%

$9.48 - $7.17

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 5, 2023

I’m sure patient will rewards high.

Nov, 11, 2022

$HKD I wonder how long they will hold it I’m super... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 1, 2023

$PALI patients ⏰⏰⏰

Jan, 23, 2023

$PALI patients are in high gear 🤑🤑🤑

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 12, 2023

$XERS On Gvoke, "better than expected growth&... See more

Nov, 4, 2022

QoQ growth would still increase by ~40% with no new patients.

HKD

AMTD Digital Inc - ADR

-24.37%

$9.48 - $7.17

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 5, 2023

I’m sure patient will rewards high.

Nov, 11, 2022

$HKD I wonder how long they will hold it I’m super patient I will be holding & adding more by days I’m not leaving 😂 soon or later it will eventually explode 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

PALI

Palisade Bio Inc

-19.56%

$2.25 - $1.81

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 1, 2023

$PALI patients ⏰⏰⏰

Jan, 23, 2023

$PALI patients are in high gear 🤑🤑🤑

Oct, 5, 2022

Conclusion: For patients undergoing elective bowel resection surgery, LB1148 was safe and well-tolerated and significantly accelerated the return of bowel function.

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 12, 2023

$XERS On Gvoke, "better than expected growth": "Opportunity remains huge, and you don't have to find patients.

Nov, 4, 2022

QoQ growth would still increase by ~40% with no new patients.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.

Oct, 20, 2022

Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.